The U.S. AI-Biotech Rally: Why Proteina, GC Genome, and ST Pharm Need Separate Cases in Korea - ST Pharm Co.,Ltd.

237690.KQ (quick overview): ST Pharm’s first-half revenue rose 45.4% to KRW 175.45B and operating profit 114% to KRW 29.84B; it disclosed a KRW 91.33B oligonucleotide API contract due by November 2027, but the undisclosed counterparty means it cannot be attributed to Moderna. FnGuide estimates 23.1x NTM P/E; valuation should be assessed alongside backlog conversion and capacity utilization. AI-discovered drugs could lift demand if candidates reach commercial production, but more clinical candidates are not confirmed orders.

Read full article (1 min)